RNA Vaccines On the Move

October 7, 2026 by Aldevron

From technical promise to practical delivery

After just a few short years, RNA vaccine development is now moving into a more mature phase, bringing exciting new possibilities. Across infectious disease and therapeutic applications, researchers are working not only on whether these technologies can succeed, but also on how to manufacture, characterize, and deliver them reliably at scale. This outlook led to intriguing conversations at the recent RNA Vaccines and Therapeutics Conference in London, as attendees discussed how current work spans the full development pathway:

• RNA design and engineering
• Lipid nanoparticle delivery (LNP)
• Manufacturing scale-up
• Analytical and quality characterization
• Clinical translation
• Next-generation platforms such as self-amplifying RNA and circular RNA

Together, these advances are expanding the range of possible applications while creating new technical and operational questions.

Key conference takeaways
RNA and lipid nanoparticle approaches remain attractive for several reasons. They can support relatively rapid development, build on evidence from earlier programs, and offer established routes for administration and manufacturing. For many infectious disease projects, technical feasibility is no longer the primary uncertainty. Progress increasingly depends on selecting the right modality, refining the process, and securing the resources needed for later-stage development.

Facing the practical challenges
Removing double-stranded RNA is an important consideration in process development and purification. Personalized cancer vaccine programs may also require specialized equipment and flexible manufacturing models. As projects move toward regulated production, teams must balance product quality, process consistency, turnaround time, and scale.

The transition to GMP manufacturing is especially important. Small-scale production can be costly, and academic grants or public funding may not cover the full expense. As a result, scientific decisions can become closely linked with economic ones. A technically suitable platform may still be difficult to advance if the manufacturing model is not affordable.

Technologies drawing interest include plasmid DNA, cell-free DNA, IVT and capping enzymes, HiCap RNA polymerase, custom mRNA production, and mRNA Cas9 applications connected with editor design. Supporting tools for mRNA-LNP processing, nanoparticle characterization, and dynamic light scattering also play a growing role in development. These needs are especially pressing for smaller programs that cannot absorb conventional production costs easily.

The science is progressing quickly, but successful translation requires more than a promising molecule. Integrated development, robust analytics, scalable processes, and accessible GMP manufacturing will determine which RNA programs can move from the laboratory toward clinical use.

• Have questions on this topic? Contact Us
• Visit our RNA Vaccines & Therapeutics page
• Have an idea for a topic? Let us know!

Subscribe to our blog